Jo Raskin

1.7k total citations
39 papers, 392 citations indexed

About

Jo Raskin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Jo Raskin has authored 39 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 5 papers in Neurology. Recurrent topics in Jo Raskin's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (8 papers). Jo Raskin is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (8 papers). Jo Raskin collaborates with scholars based in Belgium, United States and France. Jo Raskin's co-authors include Jan P. van Meerbeeck, Patrick Pauwels, Annelies Janssens, Birgitta I. Hiddinga, Xiuning Le, Enriqueta Felip, Hiroshi Sakai, Rémi Veillon, Marina Chiara Garassino and Marc Peeters and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jo Raskin

38 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jo Raskin Belgium 10 243 178 114 64 37 39 392
Naohiro Nose Japan 8 277 1.1× 219 1.2× 118 1.0× 47 0.7× 42 1.1× 23 406
Michèle Natale Germany 8 256 1.1× 293 1.6× 86 0.8× 32 0.5× 50 1.4× 25 415
Lucia Bonomi Italy 8 220 0.9× 256 1.4× 113 1.0× 36 0.6× 29 0.8× 23 433
Depei Huang China 10 197 0.8× 340 1.9× 90 0.8× 81 1.3× 23 0.6× 24 482
Yanli Xiong China 11 105 0.4× 121 0.7× 161 1.4× 74 1.2× 52 1.4× 36 338
Craig Vargo United States 8 102 0.4× 172 1.0× 114 1.0× 76 1.2× 24 0.6× 20 340
Marco Russano Italy 10 139 0.6× 239 1.3× 124 1.1× 166 2.6× 31 0.8× 37 422
Sarah Benafif United Kingdom 8 167 0.7× 131 0.7× 134 1.2× 64 1.0× 15 0.4× 23 359
Samir Darwish Italy 12 311 1.3× 250 1.4× 116 1.0× 88 1.4× 46 1.2× 17 441
Sergi Clavé Spain 10 221 0.9× 207 1.2× 76 0.7× 117 1.8× 9 0.2× 26 365

Countries citing papers authored by Jo Raskin

Since Specialization
Citations

This map shows the geographic impact of Jo Raskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo Raskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo Raskin more than expected).

Fields of papers citing papers by Jo Raskin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jo Raskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo Raskin. The network helps show where Jo Raskin may publish in the future.

Co-authorship network of co-authors of Jo Raskin

This figure shows the co-authorship network connecting the top 25 collaborators of Jo Raskin. A scholar is included among the top collaborators of Jo Raskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jo Raskin. Jo Raskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Shun, Fabrice Barlési, Robert M. Jotte, et al.. (2024). OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12. Journal of Thoracic Oncology. 19(10). S30–S30. 2 indexed citations
2.
Ibrahim, Joe, Dieter Peeters, Jo Raskin, et al.. (2024). Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases. Clinical Epigenetics. 16(1). 176–176. 1 indexed citations
3.
Viteri, Santiago, Enriqueta Felip, Frank Griesinger, et al.. (2023). 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial. Annals of Oncology. 34. S791–S792. 3 indexed citations
4.
Scherpereel, Arnaud, Jo Raskin, Renaud Louis, et al.. (2023). Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma. Frontiers in Immunology. 14. 1148798–1148798. 4 indexed citations
5.
Raskin, Jo, Annemiek Snoeckx, Annelies Janssens, et al.. (2022). New Implications of Patients’ Sex in Today’s Lung Cancer Management. Cancers. 14(14). 3399–3399. 3 indexed citations
6.
Janssens, Annelies, Jo Raskin, Patrick Pauwels, et al.. (2022). Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines. 10(3). 673–673. 5 indexed citations
7.
Griesinger, Frank, Egbert F. Smit, Rémi Veillon, et al.. (2022). 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy. Annals of Oncology. 33. S40–S41. 2 indexed citations
8.
Mazières, Julien, Marie Wislez, Christophe Dooms, et al.. (2022). LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. Annals of Oncology. 33. S1419–S1420. 27 indexed citations
9.
Zwaenepoel, Karen, Vasiliki Siozopoulou, Jo Raskin, et al.. (2021). Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy—The Role of Liquid Biopsy in Unraveling the Puzzle. Cancers. 13(7). 1675–1675. 21 indexed citations
10.
Wu, Yi‐Long, Christophe Dooms, Ernest Nadal, et al.. (2021). 1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2. Annals of Oncology. 32. S1036–S1036. 1 indexed citations
11.
Hiddinga, Birgitta I., Jo Raskin, Annelies Janssens, Patrick Pauwels, & Jan P. van Meerbeeck. (2021). Recent developments in the treatment of small cell lung cancer. European Respiratory Review. 30(161). 210079–210079. 46 indexed citations
12.
Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2021). OA05.03 Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A. Journal of Thoracic Oncology. 16(1). S5–S5. 1 indexed citations
13.
Jacobs, Julie, Christophe Deben, Christophe Hermans, et al.. (2020). Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers. 12(4). 863–863. 19 indexed citations
14.
Sorber, Laure, Peter A. van Dam, Geert Roeyen, et al.. (2020). The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE. 15(4). e0231058–e0231058. 43 indexed citations
15.
Janssens, Annelies, Luisa Vonghia, P. Michielsen, et al.. (2020). Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica. 76(5). 392–396. 3 indexed citations
16.
Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2020). 1283P Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A. Annals of Oncology. 31. S828–S829. 4 indexed citations
17.
Raskin, Jo, Veerle Surmont, Robin Cornelissen, et al.. (2018). A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Translational Lung Cancer Research. 7(5). 593–598. 24 indexed citations
18.
Raskin, Jo, Kristina Vermeersch, Stephanie Everaerts, Pascal Van Bleyenbergh, & Wim Janssens. (2018). Do-not-resuscitate orders as part of advance care planning in patients with COPD. ERJ Open Research. 4(1). 116–2017. 9 indexed citations
19.
Raskin, Jo, Pegah Masrori, Annemie Snoeckx, et al.. (2017). Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer. 109. 74–77. 17 indexed citations
20.
Raskin, Jo, Hans Slabbynck, & Karolien Beel. (2016). Derrame linfomatoso primario bilateral, no asociado al herpesvirus humano 8, en un paciente con hipervolemia crónica. Archivos de Bronconeumología. 52(9). 492–493. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naohiro Nose Breakdown of academic impact, for papers by Michèle Natale Breakdown of academic impact, for papers by Lucia Bonomi Breakdown of academic impact, for papers by Depei Huang Breakdown of academic impact, for papers by Yanli Xiong Breakdown of academic impact, for papers by Craig Vargo Breakdown of academic impact, for papers by Marco Russano Breakdown of academic impact, for papers by Sarah Benafif Breakdown of academic impact, for papers by Samir Darwish Breakdown of academic impact, for papers by Sergi Clavé
Rankless by CCL
2026